Literature DB >> 21766137

MicroRNAs dysregulated in breast cancer preferentially target key oncogenic pathways.

Weng Khong Lim1, Gos Micklem.   

Abstract

MicroRNA (miRNA) dysregulation has been associated with numerous cancers including breast cancer. The dysregulation of miRNAs in cancer has been shown to perturb various pathways, with oncogenic effects. Here we investigate the relationship between dysregulated miRNAs and pathways involved in breast cancer by integrating miRNA and mRNA expression data. From a list of dysregulated miRNAs, we started by selecting the subset that appear to be regulating genes differentially expressed in breast cancer vs. normal tissue. Individually and as a group, this subset was found to target several canonical oncogenic pathways including the p53 signalling pathway, MAPK signalling pathway, TGFβ signalling pathway, focal adhesion and cell cycle progression. These results suggest that the dysregulation of miRNAs in breast cancer not only results in widespread changes to gene expression, but also the dysregulation of key oncogenic pathways.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21766137     DOI: 10.1039/c1mb05181d

Source DB:  PubMed          Journal:  Mol Biosyst        ISSN: 1742-2051


  3 in total

1.  Identification and characterization of microRNA in the dairy goat (Capra hircus) mammary gland by Solexa deep-sequencing technology.

Authors:  Zhibin Ji; Guizhi Wang; Zhijing Xie; Chunlan Zhang; Jianmin Wang
Journal:  Mol Biol Rep       Date:  2012-07-05       Impact factor: 2.316

2.  Role of apoptosis-related miRNAs in resveratrol-induced breast cancer cell death.

Authors:  R Venkatadri; T Muni; A K V Iyer; J S Yakisich; N Azad
Journal:  Cell Death Dis       Date:  2016-02-18       Impact factor: 8.469

Review 3.  Regulatory mechanisms and clinical perspectives of miRNA in tumor radiosensitivity.

Authors:  Luqing Zhao; Ann M Bode; Ya Cao; Zigang Dong
Journal:  Carcinogenesis       Date:  2012-07-12       Impact factor: 4.944

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.